In its fourth-quarter 2025 investor letter, Latitude Investment Management highlighted stocks like Royalty Pharma (NASDAQ:RPRX).
Royalty Pharma (NASDAQ:RPRX) is a pharmaceutical company that acquires and manages royalty interests in innovative biopharma products
The one-month return of Royalty Pharma (NASDAQ:RPRX) was 7.20% while its shares traded between $32.15 and $53.47 over the last 52 weeks. On May 15, 2026, Royalty Pharma (NASDAQ:RPRX) stock closed at approximately $52.85 per share, with a market capitalization of about $30.44 billion. Latitude Investment Management stated the following regarding Royalty Pharma (NASDAQ:RPRX) in its Q4 2025 investor letter: “When sectors are hot, capital flows in with abandon, and the opposite is clearly true too.
Funding for biotech and pharmaceutical companies, which ballooned in the years of abundant cheap capital, has since collapsed. Royalty Pharma (NASDAQ:RPRX) is filling the gap, and returns on capital are rising as a result. The company has a 40-50% market share of all pharma royalties6 and remains dominant today, despite attempts at competition from large private equity firms like Blackstone.